Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Loading history...
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronickidneydisease or end-stage renaldisease Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronickidneydisease or end-stage renaldisease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Permalink Copy Page navigation Review J Vasc Surg Actions . 2021 Jan;73(1):331-340.e4. doi: 10.1016/j.jvs.2020.08.032. Epub 2020 Sep 1. Systematic review and meta-analysis of outcomes of lower extremity peripheral arterial interventions in patients with and without chronickidneydisease or end-stage renaldisease , , , , , , , , , , Affiliations Expand Affiliations 1 Section of Cardiovascular Medicine, Yale New Haven Hospital, New Haven, Conn. Electronic address: manantha@umn.edu. 2 Section
synthesis is dropping: further iron therapy may be postponed. ? A rising ferritin level and a drop in TSAT suggest an inflammatory condition: a source of inflammation may be sought: sepsis, vascular access, surgery, recent hospitalisation: further iron therapy depends on target ferritin level and clinical scenario. Renal Association Clinical Practice Guideline – Anaemia of ChronicKidneyDisease – June 2017 26 ? Ongoing high requirements for IV iron to maintain a given ferritin level also point (...) Anaemia of ChronicKidneyDisease Clinical Practice Guideline Anaemia of ChronicKidneyDisease Final Version: June 2017 Updated: February 2020 Review Date: June 2022 Authors: Dr Ashraf Mikhail Consultant Nephrologist, Abertawe Bro Morgannwg University Health Board Christopher Brown Consultant Renal Pharmacist, Abertawe Bro Morgannwg University Health Board Jennifer Ann Williams Renal Anaemia Nurse Specialist, Abertawe Bro Morgannwg University Health Board Vinod Mathrani Consultant Physician
Dapagliflozin in Patients with ChronicKidneyDisease. Patients with chronickidneydisease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronickidneydisease, with or without type 2 diabetes, is not known.We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams (...) and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidneydisease, or death from renal or cardiovascular causes.The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152
Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in ChronicKidneyDisease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Although measuring albuminuria is the preferred method for defining and staging chronickidneydisease (CKD), total urine protein or dipstick protein is often measured instead.To develop equations for converting urine protein-creatinine ratio (PCR) and dipstick protein to urine albumin (...) dipstick protein may help in CKD screening, staging, and prognosis.National Institute of Diabetes and Digestive and KidneyDiseases and National Kidney Foundation.
Intravenous thrombolysis in patients with chronickidneydisease: A systematic review and meta-analysis Intravenous thrombolysis in patients with chronickidneydisease: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Neurology Actions . 2020 Jul 14;95(2):e121-e130. doi: 10.1212/WNL.0000000000009756. Epub 2020 Jun 17. Intravenous thrombolysis in patients with chronickidneydisease: A systematic review and meta-analysis , , , , , , , , , , Affiliations
Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronickidneydisease: the BiCARB RCT Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronickidneydisease: the BiCARB RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) of Dundee, Dundee, UK 12 Ageing Clinical and Experimental Research, University of Aberdeen, Aberdeen, UK 13 Department of Medicine for the Elderly, NHS Tayside, Dundee, UK 14 John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK 15 Health Services Research Unit, University of Aberdeen, Aberdeen, UK * Corresponding author Email: {{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}} Citation
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronickidneydisease (DIAMOND): a randomised, double-blind, crossover trial Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronickidneydisease (DIAMOND): a randomised, double-blind, crossover trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronickidneydisease (DIAMOND): a randomised, double-blind, crossover trial
Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage ChronicKidneyDisease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage ChronicKidneyDisease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jun 3;e200420. doi: 10.1001/jamasurg.2020.0420. Online ahead of print. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage ChronicKidneyDisease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial , , , , , , , , , , , , , , , , , , Affiliations Expand
Effects of combined aerobic and resistance exercise on renal function in adult patients with chronickidneydisease: a systematic review and meta-analysis Effects of combined aerobic and resistance exercise on renal function in adult patients with chronickidneydisease: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jul;34(7):851-865. doi: 10.1177/0269215520924459. Epub 2020 Jun 8. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronickidneydisease: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 School of Nursing, Fujian Medical University
Potassium binders for chronic hyperkalaemia in people with chronickidneydisease. Hyperkalaemia is a common electrolyte abnormality caused by reduced renal potassium excretion in patients with chronickidneydiseases (CKD). Potassium binders, such as sodium polystyrene sulfonate and calcium polystyrene sulfonate, are widely used but may lead to constipation and other adverse gastrointestinal (GI) symptoms, reducing their tolerability. Patiromer and sodium zirconium cyclosilicate are newer ion (...) , and policy-makers.To assess the benefits and harms of potassium binders for treating chronic hyperkalaemia among adults and children with CKD.We searched the Cochrane Kidney and Transplant Register of Studies up to 10 March 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal
Effects of Allopurinol on the Progression of ChronicKidneyDisease. Elevated serum urate levels are associated with progression of chronickidneydisease. Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronickidneydisease who are at risk for progression is not known.In this randomized, controlled trial, we randomly assigned adults with stage 3 or 4 chronickidneydisease and no history of gout (...) who had a urinary albumin:creatinine ratio of 265 or higher (with albumin measured in milligrams and creatinine in grams) or an eGFR decrease of at least 3.0 ml per minute per 1.73 m2 of body-surface area in the preceding year to receive allopurinol (100 to 300 mg daily) or placebo. The primary outcome was the change in eGFR from randomization to week 104, calculated with the ChronicKidneyDisease Epidemiology Collaboration creatinine equation.Enrollment was stopped because of slow recruitment
The Management of ChronicKidneyDisease Management of ChronicKidneyDisease (CKD) (2019) - VA/DoD Clinical Practice Guidelines Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu (...) links. Get help from Veterans Crisis Line Locator Contact Search Contact Us Locator Get help from Veterans Crisis Line Search Enter your search text Button to start search More VA More VA Inside VA Budget and Performance Inside the Media Room National Observances Special Events » » » » » Management of ChronicKidneyDisease (CKD) (2019) VA/DoD Clinical Practice Guidelines Menu Menu Quick Links Enter ZIP code here Enter ZIP code here Management of ChronicKidneyDisease (CKD) (2019) Newly Updated
Oral protein-based supplements versus placebo or no treatment for people with chronickidneydisease requiring dialysis. Malnutrition is common in patients with chronickidneydisease (CKD) on dialysis. Oral protein-based nutritional supplements are often provided to patients whose oral intake is otherwise insufficient to meet their energy and protein needs. Evidence for the effectiveness of oral protein-based nutritional supplements in this population is limited.The aims of this review were (...) to determine the benefits and harms of using oral protein-based nutritional supplements to improve the nutritional state of patients with CKD requiring dialysis.We searched the Cochrane Kidney and Transplant Register of Studies up to 12 December 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP
A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in ChronicKidneyDisease A Randomized Trial of Distal Diuretics Versus Dietary Sodium Restriction for Hypertension in ChronicKidneyDisease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Create file Cancel Actions Cite Share Permalink Copy Page navigation J Am Soc Nephrol Actions . 2020 Mar;31(3):650-662. doi: 10.1681/ASN.2019090905. Epub 2020 Jan 29. A Randomized Trial of Distal Diuretics Versus Dietary Sodium Restriction for Hypertension in ChronicKidneyDisease , , , , , , , , , Affiliations Expand Affiliations 1 Divisions of Nephrology and Transplantation. 2 Dietetics, and. 3 Division of Pharmacology, Department of Pharmaceutical Sciences, University Utrecht, Utrecht
Global, regional, and national burden of chronickidneydisease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Health system planning requires careful assessment of chronickidneydisease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function (...) , for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout.The main data sources we used were published literature, vital registration systems, end-stage kidneydisease registries, and household surveys. Estimates of CKD burden were produced using a Cause
Pharmacological interventions for heart failure in people with chronickidneydisease. Approximately half of people with heart failure have chronickidneydisease (CKD). Pharmacological interventions for heart failure in people with CKD have the potential to reduce death (any cause) or hospitalisations for decompensated heart failure. However, these interventions are of uncertain benefit and may increase the risk of harm, such as hypotension and electrolyte abnormalities, in those with CKD.This (...) proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials of any pharmacological intervention for acute or chronic heart failure, among people of any age with chronickidneydisease of at least three months duration.Two authors independently screened the records to identify eligible studies and extracted data on the following dichotomous outcomes: death, hospitalisations, worsening heart failure, worsening kidney function
Disease Guideline, July 2019 Clinical Problem and Management Issues Chronickidneydisease (CKD) is an increasingly common clinical problem that raises a patient’s risk for developing several life-threatening medical conditions, including end- stage renaldisease (ESRD) and cardiovascular disease (CVD). Appropriate treatment can delay or prevent these adverse outcomes. However, CKD is often not recognized by clinicians or patients and as a result is often not optimally treated. Prevalence (...) indicating presence of abnormal kidney structure or function for 3 or more months can establish the diagnosis of CKD (Table 1). Ruling out acute (or acute on chronic) kidney injury involves clinical 13 UMHS ChronicKidneyDisease Guideline, July 2019 judgment in the clinical context of either estimated GFR (eGFR) 20% in eGFR, or an increase in serum creatinine = 0.3. During the initial evaluation of CKD, common causes and predisposing conditions for acutely decreased eGFR, including pre-renal and post
in HF patients and chronickidneydisease (CKD) with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . We conducted a systematic review evaluating the efficacy and safety of MRA in patients with HF and CKD. PubMed, Embase, and Cochrane Central databases were searched for relevant studies on patients with HF and reduced renal function (defined as eGFR <60 mL/min/1.73 m 2 ). Seven studies with 5,522 patients were included. We found 3 studies in patients with HFrEF, 1 study with HFpEF (...) Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and ChronicKidneyDisease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and ChronicKidneyDisease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily